Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ponatinib hydrochloride by Takeda Pharmaceutical for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
Ponatinib hydrochloride is under clinical development by Takeda Pharmaceutical and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...